title: Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.
abstract: We evaluated erythrocyte recovery in 121 allogeneic haematopoietic stem cell transplantation (HSCT) recipients. There were 35 major and minor ABO-incompatible transplants, respectively, including 10 bi-directionally ABO-incompatible transplants. The use of peripheral blood stem cells facilitated erythrocyte recovery, regardless of the presence or absence of major ABO-incompatibility, and was associated with a frequent detection of anti-host isohaemagglutin early after minor ABO-incompatible transplantation, which was not associated with clinically relevant haemolysis. The use of a reduced-intensity regimen combining a purine analogue and busulphan did not delay erythrocyte recovery after major ABO-incompatible transplantation, suggesting this regimen had a strong activity against host plasma cell.
authors.affiliation: Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
authors.forename: Ryuji
authors.initials: R
authors.lastname: Tanosaki
authors.forename: Kunihisa
authors.initials: K
authors.lastname: Nakai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Saito
authors.forename: Mutsuko
authors.initials: M
authors.lastname: Ohnishi
authors.forename: Hironari
authors.initials: H
authors.lastname: Niiya
authors.forename: Aki
authors.initials: A
authors.lastname: Chizuka
authors.forename: Kimikazu
authors.initials: K
authors.lastname: Yakushijin
authors.forename: Norinaga
authors.initials: N
authors.lastname: Urahama
authors.forename: Kyoji
authors.initials: K
authors.lastname: Ueda
authors.forename: Kimiko
authors.initials: K
authors.lastname: Iijima
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ando
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsubara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
authors.forename: Atsushi
authors.initials: A
authors.lastname: Makimoto
authors.forename: Yukio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.forename: Shin
authors.initials: S
authors.lastname: Mineishi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Takaue
mesh_terms: D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation; D004906:Erythrocyte Count; D004912:Erythrocytes / Q000166:cytology*; D005260:Female; D006388:Hemagglutinins / Q000032:analysis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000601:surgery* / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000601:surgery; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000601:surgery; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
chemical_list: D000017:ABO Blood-Group System; D006388:Hemagglutinins